ESR1 and breast carcinoma: Furthermore, AR-targeted therapies may offer a novel treatment avenue for human breast cancer patients, especially for those with AR-positive, estrogen receptor-negative or triple-negative subtypes, which are often resistant to conventional treatments [71,73,77,78,103,104].